Skip to content
Clinical Trials – home
Not recruiting

Bioequivalence Study of Almotriptan 12.5 mg Orodispersible vs Film‑Coated Tablet in Healthy Volunteers for Migraine Treatment

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study looks at a medication called almotriptan, which is used to treat migraine, a type of headache that can cause severe pain, nausea, and sensitivity to light. Two different tablet forms of the same medicine are being compared: one that dissolves quickly in the mouth (orodispersible tablet) and one that has a thin coating (film‑coated tablet). The purpose of the study is to see whether the body absorbs the two forms in the same way, meaning they are interchangeable for patients.

Healthy volunteers will fast (not eat) before taking a single dose of one tablet, and blood samples will be collected over several hours to measure how much of the drug reaches the bloodstream and how fast it appears. After a short break, the same participants will take the other tablet under the same conditions, and the same measurements will be repeated. This crossover design allows each person to serve as their own comparison, helping researchers determine if the two tablet types are essentially the same in how they work in the body.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and First Dose Administration

    After joining the study, you will be randomly assigned to receive either the orodispersible tablet or the film‑coated tablet of almotriptan.

    You must be fasting, which means you should not eat or drink anything other than water for a period before taking the tablet.

    A single dose of 12.5 mg almotriptan will be taken orally.

  2. Step 2

    Observation After First Dose

    Following the first dose, you will remain under observation for a period of time while the study team monitors how the medication is absorbed.

    During this time, no additional medication will be taken.

  3. Step 3

    Washout Period

    After the observation period, a washout interval will occur to allow the first dose of almotriptan to leave your system before the next dose is given.

    No study medication will be taken during this interval.

  4. Step 4

    Second Dose Administration

    You will receive the opposite formulation of almotriptan that was not taken in the first period.

    Again, you must be fasting before taking the single oral dose of 12.5 mg almotriptan.

  5. Step 5

    Final Observation and Completion

    After the second dose, you will be observed for a comparable period to the first observation phase.

    When the observation is finished, your participation in the trial is complete.

Who can join the trial?

6 criteria

  • Written consent: You must sign a form saying you understand the study, its goals, possible risks, and that you can stop at any time.
  • Age 18 to 55: You need to be between 18 and 55 years old.
  • No significant physical or mental health problems: You should not have any serious illnesses or mental conditions that could affect the study.
  • Normal medical records and physical exam: Your health check‑up and medical history must not show any important problems.
  • Normal blood and urine tests: Laboratory tests of your blood (including blood cell counts, clotting ability, chemical levels, and screening for hepatitis B, hepatitis C, and HIV) and urine must be within normal limits.
  • Normal vital signs and electrocardiogram: Basic measurements like blood pressure and heart rate, and an ECG (a test that records the heart’s electrical activity) must be normal.

Who cannot join the trial?

13 criteria

  • Having any physical (organic) or mental (psychic) illness, or having lab test results that show liver problems such as high levels of the enzymes GOT, GPT, or GGT (more than 2.5 times the normal limit) or high total bilirubin (more than 1.5 times the normal limit, unless the direct bilirubin is less than 35%).
  • Having taken part in another clinical study that used experimental medicines within the past 3 months (or within 1 month or five drug half‑lives if the other study used a marketed drug, whichever period is longer).
  • Being unable to understand or follow the study instructions or to cooperate with study procedures.
  • Having a history of trouble swallowing.
  • Being intolerant to lactose (a sugar found in milk and many foods).
  • Having taken any prescription medication in the last 15 days, or any medication (except birth‑control pills) in the 48 hours before receiving the study drug. Women must have used birth‑control methods for at least 4 weeks before the first visit and keep the same method throughout the study.
  • Having a body‑mass index (BMI) outside the range of 18.5 to 30.0. BMI is a simple calculation using weight and height (weight kg ÷ height m²) that helps assess whether a person is underweight, normal weight, or overweight.
  • Having a known allergy or sensitivity to any medication.
  • Testing positive on a drug screening test for cannabis, opiates, cocaine, or amphetamines.
  • Being a regular smoker.
  • Drinking alcohol every day or having experienced acute alcohol poisoning in the past week.
  • Having donated blood within the month before the study starts.
  • Being pregnant or breastfeeding. Women who could become pregnant must use a highly effective birth‑control method or abstain from sexual activity during the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Almotriptan

    is the test medication used in this study. It is given as an oral tablet that dissolves quickly in the mouth (orodispersible). The purpose of using this form is to see how the drug is absorbed into the body compared with a standard tablet, helping researchers determine if the new formulation works the same way as the existing one.

  • Almogran

    is the reference medication in the trial. It is a film‑coated tablet that also contains almotriptan and is taken by mouth in the usual way. This product serves as the standard against which the test tablet is compared, allowing the study to check whether the two versions deliver the same amount of medicine to the bloodstream.

What is already known about the treatment

  • Almotriptan

    The test product is an oral orodispersible tablet that melts in the mouth and is taken once at a dose of 12.5 mg. Almotriptan is an approved medicine that is widely described in medical literature for treating migraine attacks. It works by stimulating specific serotonin receptors (5‑HT1B/1D), which narrows blood vessels in the brain and blocks pain signals. Pharmacologically it belongs to the triptan class of selective serotonin receptor agonists.

  • Almogran 12,5 mg comprimidos recubiertos con película

    This comparator is an oral film‑coated tablet taken once with a dose of 12.5 mg after swallowing. Almogran is a commercial formulation of almotriptan that is also approved and well documented for the acute treatment of migraine. It acts by binding to serotonin 5‑HT1B/1D receptors, causing blood‑vessel constriction and reducing headache pain. It is classified as a triptan, a selective serotonin receptor agonist.

Investigated diseases

Migraine - Migraine is a neurological disorder marked by recurrent moderate to severe throbbing headaches, usually on one side of the head, lasting from four to seventy‑two hours. Attacks are often accompanied by nausea, vomiting, and heightened sensitivity to light or sound. Some episodes begin with an aura, a brief visual or sensory disturbance that precedes the pain. Over time, the frequency of attacks can increase, and individual episodes may become longer. Common triggers include stress, hormonal changes, certain foods, and irregular sleep patterns. The condition typically follows an episodic pattern that can evolve into a more chronic form if headaches occur on many days each month.
Trial detailsLast updated 16 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-508747-49-00Protocol codeUECHUP-ALM/23-6Estimated enrolment28 patientsSponsorQualix Pharma S.L.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.